Actively Recruiting
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2025-02-14
29
Participants Needed
1
Research Sites
196 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase II clinical study for patients with locally advanced cervical cancer, aimed at evaluating the efficacy, safety, and tolerability of Cadonilimab combined with chemotherapy as induction therapy.
CONDITIONS
Official Title
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with good compliance
- Age 18 years or older
- Histologically or pathologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma) with measurable lesions
- Initial diagnosis of stage IB3 to IVA cervical cancer (FIGO 2018 staging)
- ECOG performance status of 0 to 2
- Adequate main organ function within 7 days before treatment
You will not qualify if you...
- Other histological types of cervical cancer (e.g., neuroendocrine carcinoma, sarcoma)
- Presence of distant metastases including groin lymph nodes and nodes above L1
- Previous total hysterectomy (removal of uterus body and cervix); subtotal hysterectomy or cervical wedge resection allowed
- Anatomical or tumor-related contraindications preventing brachytherapy
- Other active malignant tumors within 2 years except certain cured local tumors
- Clinically significant bilateral hydronephrosis not relieved by nephrostomy or stent
- Prior treatment with immune checkpoint inhibitors or immune co-stimulatory factor therapies
- Use of systemic glucocorticoids or immunosuppressants above specified doses within 2 weeks
- Treatment with immunomodulatory drugs within 2 weeks
- Active systemic infections requiring treatment
- Severe infections within 4 weeks requiring hospitalization
- Major surgery, open biopsy, or trauma within 4 weeks or planned major surgery during study
- Live vaccines within 4 weeks
- Active or history of autoimmune diseases except specified stable conditions
- Certain cardiovascular diseases (NYHA class II or higher heart failure, severe arrhythmias, recent cerebrovascular events, LVEF below 50%)
- Known immunodeficiency or positive HIV test
- Active hepatitis B or C infections with specific criteria
- Active or history of inflammatory bowel disease or diverticulitis
- History of allogeneic organ or stem cell transplantation
- History of severe allergic reactions to monoclonal antibodies
- Pregnancy or breastfeeding
- Any condition posing risk or interfering with study evaluation according to investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial hosipital
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
L
Lin Ding
CONTACT
J
Jin Yang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here